Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

Blood 2002 Mar;99(6):1928-37

M. D. Anderson Cancer Center, Houston, Texas, USA.

Chronic myelogenous leukemia (CML) is caused by expression of the BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Patients with CML in accelerated phase have rapidly progressive disease and are characteristically unresponsive to existing therapies. Imatinib (formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl kinase. A total of 235 CML patients were enrolled in this study, of whom 181 had a confirmed diagnosis of accelerated phase. Patients were treated with imatinib at 400 or 600 mg/d and were evaluated for hematologic and cytogenetic response, time to progression, survival, and toxicity. Imatinib induced hematologic response in 82% of patients and sustained hematologic responses lasting at least 4 weeks in 69% (complete in 34%). The rate of major cytogenetic response was 24% (complete in 17%). Estimated 12-month progression-free and overall survival rates were 59% and 74%, respectively. Nonhematologic toxicity was usually mild or moderate, and hematologic toxicity was manageable. In comparison to 400 mg, imatinib doses of 600 mg/d led to more cytogenetic responses (28% compared to 16%), longer duration of response (79% compared to 57% at 12 months), time to disease progression (67% compared to 44% at 12 months), and overall survival (78% compared to 65% at 12 months), with no clinically relevant increase in toxicity. Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase. A daily dose of 600 mg is more effective than 400 mg, with similar toxicity.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.v99.6.1928DOI Listing
March 2002
4 Reads

Publication Analysis

Top Keywords

accelerated phase
16
cytogenetic response
8
hematologic cytogenetic
8
orally administered
8
patients cml
8
cytogenetic responses
8
cml accelerated
8
600 mg/d
8
imatinib
6
patients
6
toxicity
5
phase
5
hematologic
5
34% rate
4
17% estimated
4
estimated 12-month
4
complete 17%
4
rate major
4
major cytogenetic
4
12-month progression-free
4

Similar Publications